ERBB2 and breast carcinoma: It has been reported that breast cancer patients who responded positively to monotherapy with trastuzumab (an anti-HER2 antibody) exhibited significantly higher levels of both NK and antibody-dependent cellular cytotoxicity activities compared to nonresponders.[40] This suggests a possible correlation between therapy response and the level of these immune activities.